Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?
Allard, M.-A.; Sebagh, M.; Ruiz, A.; Guettier, C.; Paule, B.; Vibert, E.; Cunha, A.S.; Cherqui, D.; Samuel, D.; Bismuth, H.; Castaing, D.; Adam, R.
(2015) Journal of Hepatology, volume 63, issue 1, pp. 83 - 92
(Article)
Abstract
Background & Aims To investigate the prognostic significance of pathologic response (PR) after transarterial chemoembolization (TACE) in cirrhotic patients resected or transplanted for hepatocellular carcinoma (HCC), and to identify predictors of complete pathologic response (CPR). Methods Between 1990 and 2010, 373 consecutive cirrhotic patients with HCC were treated by TACE
... read more
followed by either liver resection (LR:184 patients) or liver transplantation (LT:189 patients). The PR was evaluated as the mean percentage of non-viable tumor area within each tumor. CPR was defined as the absence of any viable tumor area in all the present nodules. Results A total of 59 (32%) and 37 (20%) patients had CPR after LR and LT, respectively. Five-year overall survival (OS) was higher in patients with CPR compared to those without, after LR (58% vs. 34%; p = 0.0006) and tends to be higher after LT (84% vs. 65%; p = 0.09). The 5-year recurrence-free survival (RFS) rates were significantly higher in both groups (24% vs. 13% after LR; p = 0.008 and 94% vs. 73% after LT, p = 0.007). A cut-off value of >90% necrosis emerged as an impacting factor on patient survival after LR or LT. On multivariate analysis stratified on the type of procedure (LR or LT), PR >90% remained an independent factor of better OS and RFS. Independent factors associated with CPR were: a maximal tumor size
show less
Download/Full Text
Not available. The author may have various reasons for not providing access, for instance because it is prohibited by the commissioner of the research, or because the author is conducting further research on the subject.
Author keywords: alpha fetoprotein, cisplatin, doxorubicin, antineoplastic agent, adult, alpha fetoprotein blood level, Article, cancer patient, cancer prognosis, cancer surgery, cancer survival, chemoembolization, controlled study, female, graft recipient, human, independent variable, liver cell carcinoma, liver cirrhosis, liver nodule, liver resection, liver transplantation, long term survival, major clinical study, male, middle aged, overall survival, preoperative evaluation, priority journal, recurrence free survival, reference value, retrospective study, survival rate, treatment outcome, treatment response, tumor volume, Carcinoma, Hepatocellular, complication, follow up, intraarterial drug administration, Liver Neoplasms, procedures, prognosis, Antineoplastic Agents, Chemoembolization, Therapeutic, Female, Follow-Up Studies, Hepatectomy, Humans, Injections, Intra-Arterial, Liver Cirrhosis, Liver Transplantation, Male, Middle Aged, Prognosis, Retrospective Studies, Treatment Outcome
ISSN: 0168-8278
Note: cited By 16
(Publisher version, Peer reviewed)